Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01232829
Other study ID # NCI-2011-02537
Secondary ID NCI-2011-02537CD
Status Completed
Phase Phase 2
First received October 30, 2010
Last updated November 19, 2014
Start date October 2010
Est. completion date May 2014

Study information

Verified date June 2014
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This phase II trial is studying how well RO4929097 (gamma-secretase/Notch signalling pathway inhibitor RO4929097) works in treating patients with previously treated metastatic pancreatic cancer. RO4929097 may stop the growth of tumor cells by blocking some enzymes needed for cell growth.


Description:

PRIMARY OBJECTIVES:

I. To determine the 6-month survival of patients with previously treated metastatic pancreas cancer treated with gamma secretase RO4929097.

II. To determine the adverse events of RO4929097 in this patient population. III. To correlate changes in tumor markers with RO4929097 exposure.

SECONDARY OBJECTIVES:

I. To evaluate the response rate and overall survival of this population treated with RO4929097.

II. To correlate clinical outcome with tumor markers (including stem cell markers) obtained from pre- and post- treatment biopsies. (exploratory) III. To assess variants in genes involved in RO4929097 disposition and their relation to RO4929097 exposure.

OUTLINE: This is a multicenter study.

Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 orally (PO) once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.

Patients may undergo tumor biopsy at baseline and on days 16 or 17 of course one for biomarker and other correlative studies. Blood samples may also collected at baseline and periodically during study for pharmacokinetic and angiogenesis marker studies.

After completion of study therapy, patients are followed up periodically for 2 years.


Recruitment information / eligibility

Status Completed
Enrollment 18
Est. completion date May 2014
Est. primary completion date July 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Histologically or cytologically confirmed metastatic pancreatic adenocarcinoma

- Not amenable to potentially curative surgical resection

- At least 1 prior regimen of chemotherapy, preferably gemcitabine-based, for metastatic disease

- Evidence of disease progression

- Measurable disease defined as = 1 lesion that can be accurately measured in = 1 dimension (longest diameter to be recorded) as = 20 mm by conventional techniques or as = 10 mm by spiral CT scan

- Available archived tumor tissue (baseline core biopsies or surgical tumor blocks)

- No diagnosis by fine-needle aspiration only

- No known brain metastases

- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1 (Karnofsky 70-100%)

- White blood cell count (WBC) = 3,000/mm³

- Absolute neutrophil count (ANC) = 1,500/mm³

- Platelet count = 100,000/mm³

- Hemoglobin = 9 g/dL

- Total bilirubin normal

- Aspartate aminotransferase (AST) and Alanine Aminotransferase (ALT) = 2.5 times upper limit of normal (ULN) (5 times ULN if liver metastases present)

- Creatinine normal OR creatinine clearance = 60 mL/min

- Willingness to undergo 2 tumor biopsies, if required

- Fertile patients must use 2 forms of contraception (i.e., barrier contraception and one other method of contraception) = 4 weeks prior to, during, and for = 12 months after completion of therapy

- Negative pregnancy test

- Not pregnant or nursing

- Able to swallow pills

- No patients with malabsorption syndrome or other condition that would interfere with intestinal absorption

- No history of allergic reactions attributed to compounds of similar chemical or biologic composition to gamma secretase inhibitor RO4929097

- Not serologically positive for hepatitis A, B, or C

- No history of liver disease, other forms of hepatitis, or cirrhosis

- No uncontrolled hypocalcemia, hypomagnesemia, hyponatremia, hypophosphatemia, or hypokalemia despite adequate electrolyte supplementation

- No uncontrolled intercurrent illness including, but not limited to, any of the following:

- Ongoing or active infection

- Symptomatic congestive heart failure

- Unstable angina pectoris

- Cardiac arrhythmia other than chronic, stable atrial fibrillation

- Psychiatric illness/social situations that would limit compliance with study requirements

- No baseline QTcF > 450 msec (male) or QTcF > 470 msec (female)

- No other malignancy within the past 5 years except curatively treated basal cell carcinoma of the skin or carcinoma in-situ of the uterine cervix

- No combination antiretroviral therapy for HIV-positive patients

- Recovered to < Common Toxicity Criteria for Adverse Effects (NCI CTCAE) grade 2 toxicities from prior therapy

- More than 3 weeks since prior chemotherapy for metastatic disease (6 weeks for carmustine or mitomycin C)

- At least 4 weeks since prior radiotherapy

- Concurrent low-molecular weight heparin (LMWH) or full-dose coumadin allowed

- International normalized ratio (INR) must be monitored as clinically indicated

- No other concurrent investigational agents

- No concurrent strong cytochrome P450 3A4 (CYP3A4) inhibitors or inducers, including the following:

- Strong inhibitors: Amiodarone, erythromycin, clarithromycin, grapefruit juice, isoniazid, ketoconazole, itraconazole, or nefazodone

- Patients taken off strong inhibitors allowed provided they have = 1-week washout period

- Strong inducers: Carbamazepine, pentobarbital, phenobarbital, phenytoin, Rifabutin, Rifampin, or St. John wort

- Patients taken off strong inducers allowed provided they have = 2-week washout period

- No concurrent antiarrhythmics or other medications known to prolong QTc

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
gamma-secretase/Notch signalling pathway inhibitor RO4929097
Given PO

Locations

Country Name City State
United States University of Colorado Cancer Center - Anschutz Cancer Pavilion Aurora Colorado
United States Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore Maryland
United States University of Colorado Denver Colorado

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Survival Rate The primary endpoint of the study was 6-month survival. The proportion of successes was estimated by the number of successes divided by the total number of evaluable patients. 6 months No
Secondary Survival Survival was estimated using the Kaplan-Meier (1958) method. From registration to death due to any cause, assessed up to 2 years No
Secondary Time to Disease Progression Eighteen patients were evaluable for the time to disease progression endpoint. From registration to documentation of disease progression, assessed up to 2 years No
See also
  Status Clinical Trial Phase
Terminated NCT02495896 - Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors Phase 1
Completed NCT02005315 - A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer Phase 1
Completed NCT01453153 - Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer Phase 1/Phase 2
Completed NCT01064622 - Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer Phase 1/Phase 2
Completed NCT00095966 - Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Phase 2
Completed NCT02178436 - Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer Phase 1/Phase 2
Completed NCT01846520 - Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers N/A
Completed NCT01647828 - A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer Phase 1/Phase 2
Completed NCT01191684 - Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer Phase 1
Terminated NCT01555489 - Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca Phase 2
Terminated NCT01233505 - Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors Phase 1
Completed NCT00735917 - Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer Phase 2
Completed NCT02896907 - Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery Early Phase 1
Completed NCT02307539 - Palliative Care in Improving Quality of Life in Patients With Newly Diagnosed Pancreatic Cancer N/A
Completed NCT02050178 - Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer Phase 1
Completed NCT01488552 - Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer Phase 1/Phase 2
Completed NCT01222689 - Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Phase 2
Completed NCT00397787 - Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine Phase 2
Completed NCT00028496 - Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer Phase 1
Completed NCT01893801 - Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA Phase 1/Phase 2